Literature DB >> 34974279

Comment on DKK1 inhibits canonical Wnt signaling in human papillomavirus-positive penile cancer cells.

Haissa O Brito1, José de Ribamar Rodrigues Calixto2, Rui Medeiros3, Rui M Gil da Costa4.   

Abstract

Entities:  

Year:  2021        PMID: 34974279      PMCID: PMC8732796          DOI: 10.1016/j.tranon.2021.101326

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


× No keyword cloud information.
Penile squamous cell carcinoma is a neglected disease whose global distribution reflects the health disparities between developed and developing countries. This type of cancer most commonly affects developing countries in Africa and South America with age-standardized incidence rates reaching up to 6.15 per 100,000 in certain areas where penile cancer constitutes a significant public health concern [1]. The current classification of penile cancer broadly distinguishes between two forms of the disease, one induced by human papillomavirus (HPV) infection and another presumably driven by poor hygiene and chronic inflammation as observed, e.g. in patients with untreated phymosis [2]. The first form of the disease is characterized by the presence of HPV DNA, expression of HPV oncogenes, overexpression of p16INK4a and includes specific histological subtypes most frequently showing warty or basaloid morphology and viral cytopathic effects. Conversely, non-HPV related penile cancer shows distinctive histological morphology (e.g. the "usual" histological subtype) and molecular characteristics, typically with no p16INK4a accumulation. Two large scale studies have estimated the worldwide proportion of HPV-related penile cancers at 30–50% of total penile SCCs, but the frequency of HPV-related versus HPV-negative disease varies greatly between different world regions [3,4]. Histological grading and TNM staging are key elements to establish the prognosis of penile cancer patients, While localized lesions may be treated surgically, high-grade lesions and those showing lymph node involvement are eligible for chemoradiotherapy, often involving platinum-based chemotherapy. However, platinum chemoresistance via loss of p53 and phosphatase and tensin homolog (PTEN) or via up-regulation of the epithelial growth factor receptor (EGFR) is common and the prognosis for lymph node-positive patients remains dismal, as recently reviewed [5]. The rarity of the disease and its low incidence in developed countries, together with the paucity of models for pre-clinical research have long delayed the development of new therapeutic approaches for penile cancer patients. However, a number of ongoing clinical trials are now testing new agents or drug combinations in penile cancer patients, as previously reviewed. Multiple in vitro and in vivo models for translational research have also been reported in recent years [6], although none are available commercially. Among these are the first cell lines representing HPV-positive penile cancer, reported by a German team. In the present issue of Translational Oncology, the same research team reports the use of this new research tool to provide important insights into the regulation of signaling via the wingless-type integration site (Wnt) pathway and its biopathological implications in HPV-related penile cancer [7]. this work is a great example of how the newly described preclinical models can contribute for translational research on penile cancer. Previous studies suggested that Wnt signaling was active in penile cancer regardless of its HPV status [8], although its possible association with disease outcome remained obscure. Interestingly, a recently disclosed mouse model of HPV-negative penile cancer partially relies in adenomatous poliposis coli (Apc) activating mutations leading to Wnt activation, in cooperation with Smad4 mutations [9]. Wnt signaling is highly significant for cancer progression and in some solid malignancies Wnt promotes chemorresistance [10], which remains a major challenge in penile cancer as discussed in the previous paragraphs. Therefore, determining the role of Wnt in penile cancer is an important issue with potentially major clinical implications. The authors employed three cell lines representing a primary and two lymph node metastases from patients with HPV-positive penile cancer to study the transcriptional status of the Wnt pathway and observed an up-regulation of markers related to canonical Wnt signaling, compared with normal foreskin keratinocytes. In an elegant experiment employing 3D raft organotypic cell cultures, normal foreskin keratinocytes transduced with the HPV16 E6 and E7 oncogenes showed significantly up-regulated protein expression of the Wnt enhancer leucine rich repeat containing G protein coupled receptor 6 (LGR6). This was associated with higher expression of Wnt target genes such as SRY-box transcription factor 2 (SOX2) and octamer-binding transcription factor 4 (OCT4). These observations support the hypothesis that HPV16 may enhance Wnt signaling via upregulation of LGR proteins. Surprisingly, neither HPV-positive cells nor HPV-positive and HPV-negative penile cancer samples from Russian and German patient cohorts showed nuclear translocation of the pivotal Wnt factor β-catenin. A reporter gene assay also failed to show β-catenin nuclear translocation in response to stimulation with Wnt3. These observations were at odds with the author's previous findings and suggested that, despite the increased expression of Wnt ligands and receptors, there is actually no active Wnt signaling in HPV-positive penile cancer. The authors explained this discrepancy by the accumulation of Wnt inhibitors, particularly Dickkopf 1 (DKK1), which was found at high levels in HPV-positive cell lines and was able to inhibit Wnt signaling in vitro, as shown by gene reporter assays. In this context, the authors propose that DKK1 expression is driven by SOX2, itself upregulated by HPV16 E7, promoting cancer cell stemness and immune evasion. Importantly, within HPV-positive clinical specimens, DKK1 accumulation was strongly associated with higher histological grade and TNM stage, supporting its potential role as a biomarker for tumor aggressiveness. Additional studies are required to determine the potential associations of DKK1 expression in blood and tumor tissues with disease outcome. Overall, this remarkable study by Bley et al. adds new layers of complexity to our understanding of Wnt regulation on penile cancer. The author's approach also highlights the value of newly developed models for translational research on this neglected disease. The use of other complementary models, representing HPV-positive and HPV-negative disease, should be able to further elucidate the role of Wnt regulators in penile cancer. Given the limited availability of penile cancer cell lines, international cooperation efforts are urgently needed to bridge this gap.

CRediT authorship contribution statement

Haissa O. Brito: Writing – original draft, Writing – review & editing. José de Ribamar Rodrigues Calixto: Writing – review & editing. Rui Medeiros: Writing – review & editing. Rui M. Gil da Costa: Conceptualization, Writing – original draft, Writing – review & editing.

Declaration of Competing Interest

The authors have no conflicts of interest to declare.
  10 in total

1.  Prevalence of human papillomavirus DNA and p16INK4a in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis.

Authors:  Tina Bech Olesen; Freja Lærke Sand; Christina Louise Rasmussen; Vanna Albieri; Birgitte Grønkær Toft; Bodil Norrild; Christian Munk; Susanne Krüger Kjær
Journal:  Lancet Oncol       Date:  2018-12-17       Impact factor: 41.316

Review 2.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.

Authors:  Holger Moch; Antonio L Cubilla; Peter A Humphrey; Victor E Reuter; Thomas M Ulbright
Journal:  Eur Urol       Date:  2016-02-28       Impact factor: 20.096

3.  Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.

Authors:  Yu Sun; Judith Campisi; Celestia Higano; Tomasz M Beer; Peggy Porter; Ilsa Coleman; Lawrence True; Peter S Nelson
Journal:  Nat Med       Date:  2012-09       Impact factor: 53.440

4.  Role of Human Papillomavirus in Penile Carcinomas Worldwide.

Authors:  Laia Alemany; Antonio Cubilla; Gordana Halec; Elena Kasamatsu; Beatriz Quirós; Emili Masferrer; Sara Tous; Belén Lloveras; Gustavo Hernández-Suarez; Ray Lonsdale; Leopoldo Tinoco; Maria Alejo; Isabel Alvarado-Cabrero; Jan Laco; Nuria Guimerà; Enrique Poblet; Luis E Lombardi; Christine Bergeron; Omar Clavero; Hai-Rim Shin; Annabelle Ferrera; Ana Felix; Julieta Germar; Vaclav Mandys; Christine Clavel; Maria Tzardi; Luis E Pons; Vincent Wain; Eugenia Cruz; Carla Molina; Jose D Mota; Robert Jach; Julio Velasco; Carla Carrilho; Ruben López-Revilla; Marc T Goodman; Wim G Quint; Xavier Castellsagué; Ignacio Bravo; Michael Pawlita; Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé
Journal:  Eur Urol       Date:  2016-01-05       Impact factor: 20.096

5.  Targets of Wnt/ß-catenin transcription in penile carcinoma.

Authors:  Manit Arya; Christopher Thrasivoulou; Rui Henrique; Michael Millar; Ruth Hamblin; Reena Davda; Kristina Aare; John R Masters; Calum Thomson; Asif Muneer; Hitendra R H Patel; Aamir Ahmed
Journal:  PLoS One       Date:  2015-04-22       Impact factor: 3.240

6.  Penile cancer in Maranhão, Northeast Brazil: the highest incidence globally?

Authors:  Ronald Wagner Pereira Coelho; Jaqueline Diniz Pinho; Janise Silva Moreno; Dimitrius Vidal E Oliveira Garbis; Athiene Maniva Teixeira do Nascimento; Joyce Santos Larges; José Ribamar Rodrigues Calixto; Leandra Naira Zambelli Ramalho; Antônio Augusto Moura da Silva; Leudivan Ribeiro Nogueira; Laisson de Moura Feitoza; Gyl Eanes Barros Silva
Journal:  BMC Urol       Date:  2018-05-29       Impact factor: 2.264

7.  Effective combinatorial immunotherapy for penile squamous cell carcinoma.

Authors:  Tianhe Huang; Xi Cheng; Jad Chahoud; Ahmed Sarhan; Pheroze Tamboli; Priya Rao; Ming Guo; Ganiraju Manyam; Li Zhang; Yu Xiang; Leng Han; Xiaoying Shang; Pingna Deng; Yanting Luo; Xuemin Lu; Shan Feng; Magaly Martinez Ferrer; Y Alan Wang; Ronald A DePinho; Curtis A Pettaway; Xin Lu
Journal:  Nat Commun       Date:  2020-05-01       Impact factor: 14.919

Review 8.  Experimental Models for Studying HPV-Positive and HPV-Negative Penile Cancer: New Tools for An Old Disease.

Authors:  Beatriz Medeiros-Fonseca; Antonio Cubilla; Haissa Brito; Tânia Martins; Rui Medeiros; Paula Oliveira; Rui M Gil da Costa
Journal:  Cancers (Basel)       Date:  2021-01-26       Impact factor: 6.639

Review 9.  Systemic treatment of penile squamous cell carcinoma-hurdles and hopes of preclinical models and clinical regimens: a narrative review.

Authors:  Silvia Regina Rogatto; Igor Tsaur; Anita Thomas; Luisa Matos do Canto Alvim; Claudia Aparecida Rainho; Eva Juengel; Roman Alexander Blaheta; Philippe E Spiess
Journal:  Transl Androl Urol       Date:  2021-10

Review 10.  DKK1 inhibits canonical Wnt signaling in human papillomavirus-positive penile cancer cells.

Authors:  Isabelle Ariane Bley; Anabel Zwick; Muriel Charlotte Hans; Katrin Thieser; Viktoria Wagner; Nicole Ludwig; Oybek Khalmurzaev; Vsevolod Borisovich Matveev; Philine Loertzer; Alexey Pryalukhin; Arndt Hartmann; Carol-Immanuel Geppert; Hagen Loertzer; Heiko Wunderlich; Carsten Maik Naumann; Holger Kalthoff; Kerstin Junker; Sigrun Smola; Stefan Lohse
Journal:  Transl Oncol       Date:  2021-11-10       Impact factor: 4.243

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.